Seattle Cancer Care Alliance Clinicians Present New Research at 63rd Annual Meeting of the American Society of Hematology

Dec. 9, 2021 20:32 UTC

Key research spans CAR T-cell therapies and treatments for myeloma, leukemia and more.

SEATTLE--(BUSINESS WIRE)-- Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network (NCCN)-designated cancer center in Washington state, today announced that more than 20 of the organization’s clinicians will showcase new research at the 63^rd Annual Meeting of the American Society of Hematology (ASH), taking place December 11-14, 2021, in Atlanta.

SCCA clinicians and researchers will unveil findings on areas of investigation into treatments for patients with various hematological malignancies, including lymphoma, leukemia and myeloma. Clinicians will discuss findings on CAR-T therapies targeting CD20 cells, multiple myeloma and chronic lymphocytic leukemia. Key research also includes findings on hematopoietic stem cell transplant (HCT) and outcomes and utilization for a range of treatments.

“Our team at Seattle Cancer Care Alliance is committed to understanding, developing and advancing cutting-edge cancer treatments,” said Nancy Davidson, MD, president and executive director of SCCA. “Our researchers and clinicians are known leaders in the hematological clinical research space; we are proud of their work and continued contributions to this space. We look forward to energized discussion on the implications of the research presented and the role the research plays in contributing to expanded treatment options for patients.”

For more information about SCCA physician-researchers presenting their pioneering research at the 63rd ASH annual meeting, visit https://www.seattlecca.org/conference/ash-2021.

Below is a list of SCCA’s lead abstracts and presentations:

CAR-T Therapies:

Abstract: 3872 - Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

• SCCA Author: Mazyar Shadman, MD, MPH

Abstract: 2815 - Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8+ T-Cells: Preliminary Results from a Phase 1 Study

• SCCA Author: Alexandre V. Hirayama, MD

Abstract: 1749 - Long-Term Follow-up and Single-Cell Multiomics Characteristics of Infusion Products in Patients with Chronic Lymphocytic Leukemia Treated with CD19 CAR-T Cells

• SCCA Author: Alexandre V. Hirayama, MD

Abstract: 551 - Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

• SCCA Author: Andrew J. Cowan, MD

Abstract: 905 - Clinical Translation of SC-DARIC33: A Pharmacologically Controlled CD33-Targeted Anti-AML CAR T Cell Product Regulated By Low Nanomolar Concentrations of Rapamycin

• SCCA Author: Jacob S. Appelbaum, MD, PhD

Abstract: 470 - SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

• SCCA Author: Corinne Summers, MD

Hematopoietic Stem Cell Transplant (HCT):

Abstract: 645 - Donor Bone Marrow Derived Macrophage Engraftment into the Central Nervous System of Allogeneic Transplant Patients

• SCCA Author: Keith R. Loeb, MD, PhD

Abstract: 646 - Non-Genetic Determinants of Clonotypic T Cell Expansion Following Allogeneic Stem Cell Transplant

• SCCA Author: Albert C. Yeh, MD

Abstract: 2868 - COVID-19 in Pediatric Hematopoietic Cell Transplant Recipients: A CIBMTR Study

• SCCA Author: Neel S. Bhatt, MBBS, MPH

Abstract: 648 - Early Cytomegalovirus Reactivation after Allogenic Bone Marrow Transplantation Is Associated with the Loss of Recipient-Derived Humoral Immunity and Is Reduced By IL-6 Inhibition

• SCCA Author: Ping Zhang, MD

Treatments of Hematological Malignancies:

Abstract: 1208 - The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study

• SCCA Author: Ryan D. Cassaday, MD

Abstract: 34 - A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

• SCCA Author: Roland B. Walter, MD, PhD, MS

Abstract: 813 - Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)

• SCCA Author: Ryan C. Lynch, MD

Abstract: 233 - Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma

• SCCA Author: Ryan C. Lynch, MD

Abstract: 1410 - Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

• SCCA Author: Mazyar Shadman, MD, MPH

Abstract: 1363 - Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures

• SCCA Author: Solomon A. Graf, MD

Abstract: 799 - Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG

• SCCA Author: Derek L. Stirewalt, MD

Abstract: 403 - CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04

• SCCA Author: Corinne Summers, MD

Abstract: 2339 - Infectious Complications after Intensive Chemotherapy with CLAG-M or ‘7+3’ for Adults with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

• SCCA Author: Anna B. Halpern, MD

Abstract: 3341 - Development of Astatine-211 (211At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies

• SCCA Author: Johnnie J. Orozco, MD, PhD

Abstract: 2745 - TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma

• SCCA Author: Leona Holmberg, MD, PhD

Abstract: 3909 - Patient-Reported Outcomes (PROs) Among Patients with Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

• SCCA Author: Stephanie J. Lee, MD, MPH

Abstract: 2094 - Absence of Hyperactivation of Fibrinolysis Explains the Lack of Hemostatic Efficacy of Prophylactic Tranexamic Acid (TXA) in Hypoproliferative Thrombocytopenia

• SCCA Author: Terry B. Gernsheimer, MD

Abstract: 1609 - The IL-2/IL-15 Mimetic NL-201 Prevents Myeloma Relapse after ASCT By Expanding Highly Cytolytic T Cells in the Bone Marrow That Are Resistant to Exhaustion

• SCCA Author: Simone A. Minnie, PhD

Abstract: 328 - The Combination of Anti-Tigit and Lenalidomide Promotes Synergistic Myeloma-Specific Immunity after ASCT

• SCCA Author: Simone A. Minnie, PhD

About Seattle Cancer Care Alliance

Seattle Cancer Care Alliance brings together the leading research teams and cancer specialists from Fred Hutch, Seattle Children’s and UW Medicine — one extraordinary group whose sole purpose is the pursuit of better, longer, richer lives for our patients. Based in Seattle’s South Lake Union neighborhood, Seattle Cancer Care Alliance has ten clinical care sites in the region, including Seattle Cancer Care Alliance Proton Therapy Center, a medical oncology clinic at EvergreenHealth in Kirkland; hematology/medical oncology and infusion services at Overlake Medical Center in Bellevue, medical and radiation oncology clinics at UW Medical Center - Northwest Seattle and medical oncology services at SCCA Issaquah, as well as Network affiliations with hospitals in five states. For more information about SCCA, visit seattlecca.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211209006013/en/